Sign up to save your podcasts
Or
Share How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Targeted Mutations
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Targeted Mutations
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings.
Episode Highlights:
• The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making.
• Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy.
• Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy.
• Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies.
• Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies.
Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
View all episodes
By Oncology Brothers
4.9
4242 ratings
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings.
Episode Highlights:
• The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making.
• Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy.
• Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy.
• Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies.
• Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies.
Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
121 Listeners
ASCO Daily News
57 Listeners
Pod Save America
87,390 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
205 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
22 Listeners
Lung Cancer Considered
26 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Oncology On The Go
4 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
193 Listeners
Oncology for the Inquisitive Mind
4 Listeners